Quadruple Therapy in HFrEF: What Happens Next?
-
By
January 29, 2026
-
3 min
-
1
Only 7.2% of eligible patients received quadruple therapy.
-
2
19% mortality within 1 year post-discharge.
-
3
37% faced death or rehospitalization for heart failure.
-
4
Median healthcare cost per patient approached $28,
-
5
Study limited to patients aged 65 and older.
-
6
Medication adherence impacts outcomes.
-
7
Researchers noted financial relationships with industry partners.
-
8
Need for enhanced access to therapies highlighted.
-
A study published in JAMA Cardiology reveals that only 7.2% of eligible US patients hospitalized for heart failure with reduced ejection fraction (HFrEF) received guideline-recommended quadruple therapy at discharge. Conducted on 20,651 patients aged 65 and older, the research highlighted a high mortality risk, with 19% of patients dying within a year post-discharge and nearly 37% either dying or being readmitted for heart failure. The analysis suggests a significant clinical burden and high healthcare costs, reinforcing the need for improved medication adherence and access.
-
1
Only 7.2% of eligible patients received quadruple therapy.
-
2
19% mortality within 1 year post-discharge.
-
3
37% faced death or rehospitalization for heart failure.
-
4
Median healthcare cost per patient approached $28,
-
5
Study limited to patients aged 65 and older.
-
6
Medication adherence impacts outcomes.
-
7
Researchers noted financial relationships with industry partners.
-
8
Need for enhanced access to therapies highlighted.
Listen Tab content
